Life Sciences Interface

10micron cryosection of microneedle treated human skin
10micron cryosection of microneedle treated human skin

The Life Sciences Interface (LSI) Group is exploiting the extensive design, fabrication and characterisation tools available in Tyndall, to enable manipulation, detection and characterisation of a wide range of small molecules, nucleic acids, proteins and cells. Researchers in the LSI Group have a track record of taking concepts through the complete development cycle from design, through to device fabrication, to prototype system integration, and have also worked with commercial partners to facilitate product development and validation. Ongoing research programmes within the LSI Group include the development of:

  • nanopore platforms for nanoscale sensing,
  • surface engineering, microfluidics, packaging, signal processing, together with easy to use control systems
  • lab-on-chip systems for detection/analysis of small molecules, nucleic acids, proteins and / or cells,
  • next generation medical devices,
  • devices for neural interfacing,
  • innovative solutions for drug delivery,
  • systems for enabling continuous monitoring for healthcare and environmental applications,
  • near-patient / point-of-care diagnostic systems for molecular diagnostics
  • devices and systems for analysis of chemical and biological parameters for water quality monitoring
  • multiparameter cell sensing platforms

The multidisciplinary researchers in the LSI group are actively collaborating with national and international partners across several projects. Collaborations with various clinicians and clinical experts (especially those based in the Royal College of Surgeons in Ireland (RCSI)), provide the full spectrum of expertise to enable the development of next generation healthcare technologies from concept right through to clinical validation. Researchers from the LSI group are collaborators in the Biomedical Diagnostic Institute (BDI), CLARITY (sensors for the web), the Competence Centre for Applied Nanotechnology (CCAN), the National Biophotonics Imaging Platform (NBIP) and collaborate with researchers from many of Irelands third levels institurions through the National Access Programme (based in Tyndall). Tyndall is and has been very successful in attracting funding from the various European Framework programmes, and is a leading research institute at Europe level for health and environment related technology research.


Dr. Paul Galvin
Head of Life Sciences Interface Group, Tyndall National Institute


Ireland fund ecsf ucc
Privacy - Legal Statements
Tyndall - All rights reserved - 2018